Werewolf Therapeutics HOWL Cash Flow Statement (2020-2026)

NASDAQ HOWL
$1.03 -0.02 (-1.90%)
At close: Oct 21, 2026 · 4:00 PM EDT
Reported Financials

Werewolf Therapeutics Quarterly Cash Flow Statement

Periods 26 quarters
Latest Jun 2026

Werewolf Therapeutics reported cash from operations of $6.63M and free cash flow of $6.63M for the quarter ended Jun 2026, up 143.7% year over year. This cash flow statement covers 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-13.76M-17.87M-15.34M-14.59M-11.94M-11.93M-11.98M-5.10M-8.29M-12.00M-16.19M-17.25M-16.67M-20.40M-18.09M-17.98M-16.37M-8.38M-13.53M3.67M
Depreciation and DepletionDep. & Depletion
0.10M0.02M0.10M0.19M0.40M0.42M0.43M0.43M0.45M0.46M0.46M0.45M0.45M0.44M0.43M0.41M0.40M0.40M0.40M2.45M
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges
0.20M0.06M
Depreciation & Amortization (CF)Dep. & Amort.
0.10M0.02M0.10M0.19M0.40M0.42M0.43M0.43M0.45M0.46M0.46M0.45M0.45M0.44M0.43M0.41M0.40M0.40M0.40M2.45M
Share-based CompensationStock Comp.
1.48M1.30M1.75M1.78M1.94M1.94M2.11M1.93M2.10M1.87M2.31M2.60M2.01M1.91M2.01M1.79M1.23M1.21M0.93M0.42M
Gains from Investment SecuritiesGains Investment
-1.03M1.61M0.11M-0.09M0.17M0.02M0.03M1.86M0.67M0.03M
Other non-cash itemsOther Non-Cash
0.17M0.01M0.38M0.84M0.30M-0.11M0.35M0.46M0.47M0.55M0.66M0.68M0.79M0.81M2.25M
Change in Working Capital
Change in Account PayablesChange Payables
-1.51M0.65M-0.67M0.81M-0.91M-0.11M0.96M-0.62M-0.10M
Change in Accured ExpensesChange Accured Exp.
2.14M3.12M-2.03M5.56M1.15M-1.63M0.90M-3.92M-2.27M0.95M-2.47M2.48M0.85M2.59M-3.37M1.02M-1.21M-3.95M1.92M-0.22M
Change in Other Operating AssetsOther Assets Change
0.84M0.19M-1.79M7.94M2.75M-1.71M-2.10M1.23M-0.89M-5.10M-1.28M0.62M-0.73M-0.63M-0.13M0.71M-0.46M-0.97M-0.16M-0.48M
Change in Other Operating LiabilitiesOther Liabilities Change
13.26M-2.77M-3.81M-2.84M-3.44M-0.71M-1.42M-1.15M-1.28M-0.35M-0.17M-0.56M-0.39M-0.40M-0.21M-0.62M-2.77M
Other Working Capital ChangesOther WC Changes
-0.17M0.26M0.08M-0.20M-0.38M-0.48M-0.50M-0.51M0.18M3.68M0.13M-1.90M0.38M0.46M-0.43M-1.09M0.06M0.76M-0.45M-2.29M
Cash from OperationsCash from Ops.
-12.42M-12.67M-13.95M-0.30M-14.47M-11.87M-9.90M-10.92M-7.21M-4.59M-15.30M-14.18M-12.46M-14.25M-18.95M-15.16M-15.16M-11.02M-10.60M6.63M
Investing Activities
Capital ExpendituresCapex
0.10M0.27M0.03M1.11M1.95M0.52M0.17M0.18M0.22M0.20M0.11M0.02M0.00M0.12M
Change in Property, Plant and EquipmentChange in PP&E
-0.10M-0.27M-0.03M-1.11M-1.95M-0.52M-0.17M-0.18M-0.22M-0.20M-0.11M-0.02M0.00M-0.12M
Cash from Investing ActivitiesCash from Investing
-0.10M-0.27M-0.03M-1.11M-1.95M-0.52M-0.17M-0.18M-0.22M-0.20M-0.11M-0.02M0.00M-0.12M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance
40.00M30.00M
Non-Current Debt
40.00M30.00M
Net Debt Issuances and RepaymentsNet Debt Issuance
40.00M30.00M
Change in Capital Stock
Common Stock IssuedStock Issued
0.03M0.03M0.16M3.65M11.18M1.00M8.62M0.69M0.04M9.07M20.26M0.95M-0.01M2.55M0.39M3.27M2.37M
Net Shares Issued and RepurchasedNet Shares Issued
0.03M0.03M0.16M3.65M11.18M1.00M8.62M0.69M0.04M9.07M20.26M0.95M-0.01M2.55M0.39M3.27M2.37M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
0.03M0.03M0.16M3.65M11.18M1.00M8.62M0.69M0.04M9.07M20.26M0.95M-0.01M2.55M0.39M3.27M2.37M
Other financing activitiesOther financing
-0.30M0.01M-0.24M-0.10M0.25M-0.09M0.09M
Cash from Financing ActivitiesCash from Financing
-0.28M0.04M0.16M3.42M11.08M1.26M48.62M0.69M0.04M9.07M20.26M-9.72M-0.01M2.55M0.39M3.27M2.37M
Additional items
Change in Cash
-12.80M-12.91M-13.82M2.00M-5.35M-11.13M38.56M-10.41M-7.39M4.29M4.85M-23.91M-12.47M-11.83M-18.95M-14.78M-11.88M-8.66M-10.60M-25.37M
Ending Cash Balance
171.74M158.83M145.01M147.01M141.66M130.53M169.09M158.68M151.29M155.58M160.43M136.51M124.04M112.22M93.27M78.49M66.61M57.95M47.35M22.00M
Free Cash FlowFCF
-12.52M-12.95M-13.98M-1.41M-16.43M-12.39M-10.07M-11.10M-7.43M-4.78M-15.41M-14.19M-12.47M-14.38M-18.95M-15.16M-15.16M-11.02M-10.60M6.63M
Net Cash FlowNCF
-12.80M-12.91M-13.82M2.00M-5.35M-11.13M38.56M-10.41M-7.39M4.29M4.85M-23.91M-12.47M-11.83M-18.95M-14.78M-11.88M-8.66M-10.60M6.63M
Interest Paid
0.74M0.90M0.91M0.91M0.88M0.79M0.78M0.77M0.79M0.79M0.78M0.77M0.57M

Werewolf Therapeutics Cash Flow Statement API

Pull Werewolf Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=HOWL&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY